Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

    Research output: Contribution to journalLetterResearchpeer-review

  2. Flow cytometric analysis of cerebrospinal fluid improves detection of leukaemic blasts in infants with acute lymphoblastic leukaemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Elevated blood cell counts and vascular disease with the myeloproliferative neoplasms as model diseases

    Research output: Contribution to journalReviewResearchpeer-review

  2. Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The effects of smoking on the molecular response (MR) and overall survival (OS) in patients with chronic myeloproliferative neoplasms (MPNs) have not been investigated before. We analysed a historical cohort of 498 consecutive patients diagnosed with MPNs. Moreover, we analysed a subgroup of 270 consecutive patients with MPNs with > 1 measurement of the JAK2V617F variant allele frequency. The data were analysed using Kaplan-Meier plots and Cox regression analysis, along with linear regression models. In all patients, the rate of MR was significantly higher in never-smokers compared with current smokers in the univariate model (HR, 1·9; 95% CI, 1·1-3·3; P = 0·033) and the multivariate model (HR, 1·9; 95% CI, 1·1-3·5; P = 0·029). Similar findings were observed with different cut-off values for a partial MR. A subgroup analysis including only interferon-α2-treated patients showed similar results. In multivariate analyses, the OS was significantly better for never-smokers (HR, 0·46; 95% CI, 0·29-0·75; P = 0·002) than current smokers. The differences were more pronounced in the pegylated interferon-α2-treated patients. However, no significant interaction of interferon-α2 treatment was observed. In conclusion, we found that tobacco smoking reduced the rate of MR and OS in patients with MPNs. Cessation of smoking should be encouraged.

Original languageEnglish
JournalBritish Journal of Haematology
ISSN0007-1048
DOIs
Publication statusPublished - 10 Nov 2020

ID: 61229879